STOCK TITAN

ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will attend the 12th Annual Jefferies London Healthcare Conference in-person on November 17, 2021, at 1:00 PM GMT. The conference runs from November 16-17, 2021, in-person, and virtually from November 18-19, 2021. A live webcast of the discussion will be available, with a replay accessible on ASLAN’s Investor Relations website. ASLAN is focused on developing innovative treatments for immunology and is evaluating ASLAN004 and ASLAN003 for various conditions.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif. and SINGAPORE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT. The conference will be held in-person November 16 and 17, 2021 and virtually November 18 and 19, 2021.

A live webcast of the discussion can be accessed using this link: https://wsw.com/webcast/jeff201/asln/1840068 with a replay available shortly afterwards in the News & Events section of ASLAN’s Investor Relations website at https://ir.aslanpharma.com/

Media and IR contacts

Emma Thompson
Spurwing Communications
Tel: +65 6206 7350
Email: ASLAN@spurwingcomms.com
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

 


FAQ

When will ASLAN Pharmaceuticals participate in the Jefferies London Healthcare Conference?

ASLAN Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 17, 2021, at 1:00 PM GMT.

How can I access the live webcast of ASLAN Pharmaceuticals' conference participation?

The live webcast of ASLAN Pharmaceuticals' participation can be accessed [here](https://wsw.com/webcast/jeff201/asln/1840068).

What is ASLAN Pharmaceuticals currently developing?

ASLAN Pharmaceuticals is developing ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases.

What dates will the Jefferies London Healthcare Conference be held?

The conference will take place in-person on November 16-17, 2021, and virtually on November 18-19, 2021.

Where can I find the replay of ASLAN Pharmaceuticals' conference discussion?

The replay of ASLAN Pharmaceuticals' conference discussion will be available on their Investor Relations website shortly after the event.

ASLAN Pharmaceuticals Limited American Depositary Shares

NASDAQ:ASLN

ASLN Rankings

ASLN Latest News

ASLN Stock Data

1.70M
565.67M
0.14%
13.21%
1.35%
Biotechnology
Healthcare
Link
United States of America
Singapore